| Segment / region | Type | Fiscal year | Currency | Revenue (millions) | Share of revenue |
|---|---|---|---|---|---|
| Other countries | Region | 2022 | USD | 20,054.0 | 39.7% |
| UNITED STATES | Region | 2022 | USD | 17,653.0 | 34.9% |
| GERMANY | Region | 2022 | USD | 4,278.0 | 8.5% |
| CHINA | Region | 2022 | USD | 3,128.0 | 6.2% |
| FRANCE | Region | 2022 | USD | 2,257.0 | 4.5% |
| JAPAN | Region | 2022 | USD | 2,205.0 | 4.4% |
| Country of domicile | Region | 2022 | USD | 970.0 | 1.9% |
| Other countries | Region | 2021 | USD | 20,808.0 | 40.3% |
| UNITED STATES | Region | 2021 | USD | 16,818.0 | 32.6% |
| GERMANY | Region | 2021 | USD | 4,870.0 | 9.4% |
| CHINA | Region | 2021 | USD | 3,052.0 | 5.9% |
| JAPAN | Region | 2021 | USD | 2,683.0 | 5.2% |
| FRANCE | Region | 2021 | USD | 2,522.0 | 4.9% |
| Country of domicile | Region | 2021 | USD | 873.0 | 1.7% |
| Other countries | Region | 2020 | USD | 19,038.0 | 39.1% |
| UNITED STATES | Region | 2020 | USD | 16,484.0 | 33.9% |
| GERMANY | Region | 2020 | USD | 4,518.0 | 9.3% |
| JAPAN | Region | 2020 | USD | 2,804.0 | 5.8% |
| CHINA | Region | 2020 | USD | 2,573.0 | 5.3% |
| FRANCE | Region | 2020 | USD | 2,442.0 | 5.0% |
| Country of domicile | Region | 2020 | USD | 800.0 | 1.6% |
| UNITED STATES | Region | 2019 | USD | 16,280.0 | 63.9% |
| GERMANY | Region | 2019 | USD | 4,120.0 | 16.2% |
| JAPAN | Region | 2019 | USD | 2,656.0 | 10.4% |
| FRANCE | Region | 2019 | USD | 2,442.0 | 9.6% |
| Other countries | Region | 2018 | USD | 22,169.0 | 43.8% |
| UNITED STATES | Region | 2018 | USD | 17,560.0 | 34.7% |
| GERMANY | Region | 2018 | USD | 4,184.0 | 8.3% |
| JAPAN | Region | 2018 | USD | 3,169.0 | 6.3% |
| FRANCE | Region | 2018 | USD | 2,705.0 | 5.3% |
| Country of domicile | Region | 2018 | USD | 852.0 | 1.7% |
| Top 20 products | Product | 2022 | USD | 32,137.0 | 74.3% |
| Rest of portfolio | Product | 2022 | USD | 9,159.0 | 21.2% |
| Total anti-infectives net sales | Product | 2022 | USD | 1,200.0 | 2.8% |
| Anti Infectives sold under Sandoz name | Product | 2022 | USD | 777.0 | 1.8% |
| Top 20 products | Product | 2021 | USD | 32,664.0 | 74.6% |
| Rest of portfolio | Product | 2021 | USD | 9,331.0 | 21.3% |
| Total anti-infectives net sales | Product | 2021 | USD | 1,100.0 | 2.5% |
| Anti Infectives sold under Sandoz name | Product | 2021 | USD | 707.0 | 1.6% |
| Top 20 products | Product | 2020 | USD | 29,916.0 | 75.3% |
| Rest of portfolio | Product | 2020 | USD | 9,097.0 | 22.9% |
| Anti Infectives sold under Sandoz name | Product | 2020 | USD | 694.0 | 1.8% |
| Top 20 products | Product | 2019 | USD | 28,646.0 | 73.6% |
| Rest of portfolio | Product | 2019 | USD | 9,068.0 | 23.3% |
| Anti Infectives sold under Sandoz name | Product | 2019 | USD | 784.0 | 2.0% |
| COPD | Product | 2019 | USD | 427.0 | 1.1% |
| Top 20 products | Product | 2018 | USD | 26,946.0 | 77.2% |
| Rest of portfolio | Product | 2018 | USD | 7,946.0 | 22.8% |
Product and geographic breakdowns describe the same revenue from different perspectives and should not be added together.
